Novartis’ Fabhalta ® (iptacopan) Shows Significant Long-Term Efficacy in Phase III C3 Glomerulopathy (C3G) Study, According to Investing.com
The results of the APPEAR-C3G study demonstrate the potential of Fabhalta in treating C3 glomerulopathy (C3G), an ultra-rare kidney disease with no approved treatments. Fabhalta showed sustained proteinuria reduction at 12 months, along with improvements in estimated glomerular filtration rate (eGFR) slope compared to patients’ historic rapid decline. The study also highlighted a favorable safety … Read more